Additive inhibitory effects of bromocryptine (CB-154) and medroxyprogesterone acetate (MPA) on dimethylbenz[a]anthracene (DMBA)-induced mammary tumors in the rat
Treatment for 18 days of rats bearing dimethylbenz[a]anthracene-induced mammary tumors with the synthetic medroxyprogesterone acetate (MPA) or the inhibitor of prolactin secretion 2 alpha-bromocryptine (CB-154) inhibited total tumor area to 30 +/- 7% of the original volume. Combination of the two drugs, on the other hand, caused further inhibition to 10 +/- 5% of the pretreatment tumor area. The most striking effect of combination of the two drugs is a doubling of complete responses (no detectable tumor) from 30% when either drug was used alone to 60% in animals treated with the combination therapy. Both estradiol and progesterone receptors were further decreased when MPA was added to CB-154. The present data demonstrate that combination of the synthetic progestin MPA and the inhibitor of prolactin secrection CB-154 exerts maximal inhibitory effects on the growth of the DMBA-induced mammary tumor, the most widely used in vivo model of human breast cancer.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1989 |
|---|---|
| Erschienen: |
1989 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
European journal of cancer & clinical oncology - 25(1989), 5 vom: 15. Mai, Seite 891-7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dauvois, S [VerfasserIn] |
|---|
| Themen: |
3A64E3G5ZO |
|---|
| Anmerkungen: |
Date Completed 04.08.1989 Date Revised 08.09.2019 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM02506861X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM02506861X | ||
| 003 | DE-627 | ||
| 005 | 20231221094712.0 | ||
| 007 | tu | ||
| 008 | 231221s1989 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0084.xml |
| 035 | |a (DE-627)NLM02506861X | ||
| 035 | |a (NLM)2525471 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dauvois, S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Additive inhibitory effects of bromocryptine (CB-154) and medroxyprogesterone acetate (MPA) on dimethylbenz[a]anthracene (DMBA)-induced mammary tumors in the rat |
| 264 | 1 | |c 1989 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 04.08.1989 | ||
| 500 | |a Date Revised 08.09.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Treatment for 18 days of rats bearing dimethylbenz[a]anthracene-induced mammary tumors with the synthetic medroxyprogesterone acetate (MPA) or the inhibitor of prolactin secretion 2 alpha-bromocryptine (CB-154) inhibited total tumor area to 30 +/- 7% of the original volume. Combination of the two drugs, on the other hand, caused further inhibition to 10 +/- 5% of the pretreatment tumor area. The most striking effect of combination of the two drugs is a doubling of complete responses (no detectable tumor) from 30% when either drug was used alone to 60% in animals treated with the combination therapy. Both estradiol and progesterone receptors were further decreased when MPA was added to CB-154. The present data demonstrate that combination of the synthetic progestin MPA and the inhibitor of prolactin secrection CB-154 exerts maximal inhibitory effects on the growth of the DMBA-induced mammary tumor, the most widely used in vivo model of human breast cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Receptors, Estrogen |2 NLM | |
| 650 | 7 | |a Receptors, Progesterone |2 NLM | |
| 650 | 7 | |a Bromocriptine |2 NLM | |
| 650 | 7 | |a 3A64E3G5ZO |2 NLM | |
| 650 | 7 | |a 9,10-Dimethyl-1,2-benzanthracene |2 NLM | |
| 650 | 7 | |a 57-97-6 |2 NLM | |
| 650 | 7 | |a Medroxyprogesterone Acetate |2 NLM | |
| 650 | 7 | |a C2QI4IOI2G |2 NLM | |
| 650 | 7 | |a Medroxyprogesterone |2 NLM | |
| 650 | 7 | |a HSU1C9YRES |2 NLM | |
| 700 | 1 | |a Spinola, P G |e verfasserin |4 aut | |
| 700 | 1 | |a Labrie, F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer & clinical oncology |d 1985 |g 25(1989), 5 vom: 15. Mai, Seite 891-7 |w (DE-627)NLM023902329 |x 0277-5379 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:1989 |g number:5 |g day:15 |g month:05 |g pages:891-7 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 1989 |e 5 |b 15 |c 05 |h 891-7 | ||